Tarsus Pharmaceuticals (TARS) Operating Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $168.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 60.76% year-over-year to $168.2 million; the TTM figure through Mar 2026 stood at $585.9 million (up 70.89% YoY), while the FY2025 annual figure was $522.3 million, up 72.09% from the prior year.
• Operating Expenses was $168.2 million for Q1 2026 at Tarsus Pharmaceuticals, up from $159.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $168.2 million in Q1 2026 to a low of $20.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $73.1 million across 5 years, with a median of $65.3 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses dropped 11.7% in 2022, then jumped 137.86% in 2024.
• A 5-year view of Operating Expenses shows it stood at $25.1 million in 2022, then soared by 129.54% to $57.5 million in 2023, then soared by 57.89% to $90.8 million in 2024, then jumped by 75.76% to $159.6 million in 2025, then grew by 5.34% to $168.2 million in 2026.
• The last three Operating Expenses figures came in at $168.2 million (Q1 2026), $159.6 million (Q4 2025), and $133.2 million (Q3 2025), per Business Quant data.